The design and implementation of a novel pharmacogenomic assay to study the distribution of CYP3A5*3 (rs776746) and CYP3A5*1E (rs4646453) polymorphisms and its implications to predict the response to the immunosuppressive drug tacrolimus

Abstract

Introduction: Tacrolimus is a first-line immunosuppressive agent for solid organ transplantations. Due to its narrow therapeutic index, tacrolimus demonstrates a wide inter individual variability in pharmacokinetics. Genetic polymorphisms in CYP3A5 are significant determinants of tacrolimus efficacy. Methods: A total of 100 healthy individuals from the Sri Lankan population were screened for the CYP3A5 single nucleotide polymorphisms (SNPs), CYP3A5*3 (rs776746) and CYP3A5*1E (rs4646453) using a novel single variant tetra-primer amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) assay and the results were validated by DNA sequencing